Mesothelioma Survival
The average survival for mesothelioma cancer is 1-2 years, which can vary depending on several contributing factors based on the health and age of the patient, where the patient’s mesothelioma originally formed and the treatment plan.
Some patients may have a more positive prognosis due to eligibility for surgery or participating in a clinical trial that focuses on mesothelioma research. Others outlive their initial life expectancy due to surgery effectiveness or overall health.
There are other ways to improve a mesothelioma prognosis if surgery is not an option. Prioritizing overall health is key to improving a prognosis. Implementing healthy diet and lifestyle changes can positively impact your life expectancy, as well as maintaining an optimistic outlook on life. Staying hopeful and positive can be beneficial to a patient’s mental, emotional and physical state.
Doctors typically predict people with pleural mesothelioma will live at least 12-18 months with treatment, such as immunotherapy or chemotherapy. Surgery, a more aggressive treatment, can improve a pleural mesothelioma prognosis to around two years.
Survival for early-stage (stage 1 or 2) malignant pleural mesothelioma patients:
- Patients diagnosed with stage 1 lived for an average of 22 months.
- Patients diagnosed with stage 2 live for an average of 19 months.
Survival for late-stage (stage 3 or 4) pleural mesothelioma patients:
- The average survival is around 15 months for stage 3.
- The average survival is usually 11-12 months for stage 4.
These figures include all the mesothelioma cell types (epithelioid, sarcomatoid and biphasic mesothelioma).
Unfortunately, most patients are diagnosed in stage 3 or stage 4. The disease often hides in tissue linings for years before symptoms occur, and by the time patients see their doctor and get a biopsy for diagnosis, the disease is in stage 3 or stage 4.
Peritoneal mesothelioma patients typically have the longest expected survival as the cancer does not spread as quickly.
The main staging system used for peritoneal mesothelioma is called the Peritoneal Cancer Index (PCI). It involves establishing a score for different sections of the abdomen. Depending on the score, doctors will determine a stage, or whether the cancer is localized or metastatic. Patients with localized tumors, or low PCI scores, are considered an early-stage diagnosis.
Surgical treatment for peritoneal mesothelioma depends more on overall health than on the stage of diagnosis. Cytoreductive surgery and HIPEC is the primary reason for the hopeful outcomes for malignant peritoneal mesothelioma patients. This mesothelioma treatment approach is associated with a predicted life expectancy of 3-5 years depending on specific patient factors, such as age and health.